IRD Earnings Date: Nov 11, 2026 (Estimated) — Opus Genetics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is IRD's next earnings date?
Opus Genetics, Inc. (IRD) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.14 on revenue of $1.5M.
How did IRD do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Opus Genetics, Inc. posted EPS of -$0.14 versus the -$0.16 estimate, a beat of 12.5%. Revenue was $755,000 against a $2.6M estimate. The stock's 1-day post-earnings move was -1.6%.
How much does IRD stock move after earnings?
IRD beat EPS estimates in 3 of its last 6 reported quarters. Over the last 6 reports the stock moved an average of 2.8% (up or down) in the day after earnings.
About Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.16 | -0.14 | +12.50% | $755,000 | ✅ Beat | -1.59% | -0.53% | +21.69% |
| 2026-05-12 | Q1 2026 | -0.14 | -0.75 | -435.71% | $2.2M | ❌ Miss | +1.17% | -13.28% | -24.02% |
| 2026-03-10 | Q4 2025 | -0.10 | -0.21 | -110.00% | $3.9M | ❌ Miss | +1.68% | +8.80% | +7.97% |
| 2025-11-12 | Q3 2025 | -0.13 | -0.25 | -92.31% | $3.1M | ❌ Miss | -2.54% | -4.57% | +23.86% |
| 2025-08-13 | Q2 2025 | -0.26 | -0.12 | +53.85% | $2.9M | ✅ Beat | +7.27% | +5.45% | +25.45% |
| 2025-03-31 | Q4 2024 | — | -1.27 | — | $4.3M | — | -2.79% | -12.27% | -14.36% |
| 2022-11-04 | -0.28 | -0.22 | — | — | ✅ Beat | — | — | — |
Showing last 7 quarters.